Publications by authors named "M Ticchioni"
Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression in myelodysplastic neoplasms (MPO-MDS-Valid): protocol for a multicentre diagnostic accuracy study.
BMJ Open
June 2024
Article Synopsis
- A study is investigating whether flow cytometric analysis of myeloperoxidase expression in peripheral blood can accurately rule out myelodysplastic neoplasm (MDS), potentially reducing unnecessary bone marrow aspirations for about 35% of patients.
- The MPO-MDS-Valid project involves recruiting 400 patients from multiple hospitals in France to validate the testing method by comparing it to established diagnoses made by experienced hematopathologists.
- The research has been ethically approved, and results will be shared through publication to inform medical practice and improve patient care.
In previously untreated, medically fit patients with chronic lymphocytic leukemia (CLL), research is focused on developing fixed-duration strategies to improve long-term outcomes while sparing patients from serious toxicities. The ICLL-07 trial evaluated a fixed-duration (15-month) immunochemotherapy approach in which after obinutuzumab-ibrutinib induction for 9 months, patients (n = 10) in complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) <0.01% continued only ibrutinib 420 mg/day for 6 additional months (I arm), whereas the majority (n = 115) received up to 4 cycles of fludarabine/cyclophosphamide-obinutuzumab 1000 mg alongside the ibrutinib (I-FCG arm).
View Article and Find Full Text PDFIntroduction: Data on immune response to SARS-CoV-2 vaccine in patients living with HIV (PLWH) over a period longer than 3 months are currently limited. We measured the immune response after BNT162b2 vaccination against SARS-CoV-2 in this population.
Methods: We prospectively enrolled PLWH on successful antiretroviral therapy, initiating vaccination with two doses of the BNT162b2 SARS-CoV-2 vaccine administered at six-week interval.
Article Synopsis
- The SARS-CoV-2 virus has caused global outbreaks and numerous fatalities, with some treatments available to lower mortality and hospitalization rates.
- Researchers studied IFN-γ levels as a potential biomarker to predict hospitalization risks early in infection; individuals with low IFN-γ (below 15 IU/mL) were significantly more likely to be hospitalized.
- In addition to low IFN-γ levels, factors such as being over 65 years old and unvaccinated were linked to increased hospitalization risk, highlighting the importance of early monitoring and treatment decision-making for COVID-19 patients.
The aim of this study was to evaluate the effect on immune activation of switching from a triple-drug to a dual-drug regimen in HIV-1 infected patients on successful combination antiretroviral treatment (cART). Immunadapt is a prospective study evaluating the impact of cART simplification on immune activation. We prospectively collected blood samples in HIV-1 infected patients on stable and successful cART switching from triple to dual regimens as a simplifying strategy.
View Article and Find Full Text PDF